Lulizumab pegol

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lulizumab pegol
Monoclonal antibody
Type ?
Source Humanized
Target glycoprotein CD28
Clinical data
Synonyms BMS-931699
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
Formula C552H859N149O164S4
Molar mass 52 kg/mol

Lulizumab pegol (BMS-931699) (INN[1]) is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]

This drug was developed by Bristol-Myers Squibb.

References[edit]